DIAGNOSTIC INSIGHTS FOR LIFE™
CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.
Syn-One Test named a top 2024 medical innovation by NIH. 50,000+ patients tested with Syn-One – and counting.
The Syn-One Test® from CND Life Sciences
The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.
CLIA-Certified and CAP-Accredited Pathology Lab
Dedication to Science, Research, Quality, and Reliability
Patient-Focused Mission
High Accuracy: >95% Sensitivity and Specificity
Clarity and Confidence of Syn-One
Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.
Our Commitment to Patients
We may not have coined the phrase “knowledge is power,” but it perfectly reflects our mission. Every day, patients and caregivers rely on physicians to make critical clinical decisions. That’s why we are dedicated to providing reliable diagnostic technologies and actionable insights that help optimize care.
Learn more about what drives us.
